through the Assistant Secretary for Health, on issues and topics pertaining to or associated with the protection of human research subjects.
The Subpart A Subcommittee (SAS) was established by SACHRP in October 2006 and is charged with developing recommendations for consideration by SACHRP regarding the application of subpart A of 45 CFR part 46 in the current research environment.
The Subcommittee on Harmonization (SOH) was established by SACHRP at its July 2009 meeting and charged with identifying and prioritizing areas in which regulations and/or guidelines for human subjects research adopted by various agencies or offices within HHS would benefit from harmonization, consistency, clarity, simplification and/ or coordination.
The SACHRP meeting will open to the public at 8:30 a.m., on Tuesday, March 13, 2018, followed by opening remarks from Dr. Jerry Menikoff, Director of the Office for Human Research Protections and Dr. Stephen Rosenfeld, SACHRP Chair.
The SAS and SOH subcommittees will present their recommendations regarding the description of ''key information,'' as required by the revised Common Rule's § 46.116(a)(5)(i). This will be followed by a discussion of SOH recommendations on the research use of repositories and registries under various consent models, under both the current and the revised Common Rule. The Tuesday, March 13, meeting will adjourn at approximately 5:00 p.m.
The Wednesday, March 14, meeting will begin at 8:30 a.m. The SOH will present and discuss recommendations on the European Union's General Data Protection Regulation and its impact on U.S. human subjects research. Modifications to the previous day's work will be discussed and finalized. The meeting will adjourn at approximately 4:00 p.m.
Time for public comment sessions will be allotted both days. On-site registration is required for participation in the live public comment session. Note that public comment must be relevant to issues currently being addressed by the SACHRP. Individuals submitting written statements as public comment should email or fax their comments to SACHRP at SACHRP@ hhs.gov at least five business days prior to the meeting.
Public attendance at the meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated SACHRP point of contact at the address/phone number listed above at least one week prior to the meeting. ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly reporting falsified and/or fabricated data and/or falsifying and/or fabricating data in the following two (2) papers:
• Cell 167(6): [1571] [1572] [1573] [1574] [1575] [1576] [1577] [1578] [1579] [1580] [1581] [1582] [1583] [1584] [1585] 2016 (hereafter referred to as ''Paper 1'') • Proceedings of the National Academy of Sciences 112(19):E2447-E2456, 2015 (hereafter referred to as ''Paper 2'') ORI found that Respondent engaged in research misconduct by intentional, knowing, or reckless falsification and/or fabrication of the research record by selectively reporting by inappropriate inclusion/omission or alteration of data points in ten (10) figures and falsely reporting the statistical significance based on falsified data in ten (10) figures across the two (2) papers and supplementary material. Specifically, ORI found that:
• In Paper 1, Respondent falsified and/or fabricated the research record in: - Figure 3B , by selectively omitting/ including data points in the Rescue condition - Figure 5B , by reporting a significant difference between conditions by performing statistical calculations based on fabricated primary data - Figure 5C (bottom), by selectively omitting images and conditions from the analysis - Figure 6I (bottom left), by reporting data from the same data set as Figure  6B (top) - Figure S5B , by reporting statistical significance despite performing a T test calculation that returned an insignificant p-value - Figure 7F , by reporting that error bars represented standard deviation, when they actually represented standard error of the mean (SEM.) - Figure S4D, Figure 1E , by selectively omitting data points from the analysis - Figure 2A , by selectively omitting data points from the analysis - Figure 2C (left and right), by changing selected raw measurements by multiplying with a fixed value to make the data consistent with data collected in other experiments - Figure 5B , by selectively including and omitting data points from the analysis - Figure 5C , by selectively including and omitting data points from the analysis - Figure 7A ( ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly falsely reporting a larger number of data points than actually were collected in fourteen (14) figures across the two (2) papers and supplementary materials. Specifically:
• In Paper 1, Respondent falsified and/or fabricated the reported data in: - Figure 2B Figure 5A , by reporting to have examined fifty (50) cells per condition, when only twenty-three (23), twenty-three (23), and twelve (12) for the 2mg/mL conditions (Control, KD, and Rescue, respectively) and twenty-five (25), twenty (20), and nine (9) for the 3mg/ mL conditions (Control, KD, and Rescue, respectively) were recorded - Figure 6D , by reporting ten (10) cells per condition when only eight (8) Control were recorded - Figure 7D , by reporting four (4) mice for each of two (2) independent clones (8 total) for each condition when only four (4) Vector+GFP, four (4) WT, and two (2) B16 conditions were examined - Figure S2E (7) figures across the two (2) papers and supplementary materials. Specifically:
• In Paper 1, Respondent falsified and/or fabricated the record in: - Figure 5B (top right), by reporting results of 8 and 12 um pore migration, which did not originate from experimental observations - Figure 5B (bottom left), by reporting results for the Rescue condition, which did not originate from experimental observations - Figure 5B (left) , by using selected regions from the same original image to represent both the control (top) and rescue conditions (bottom) - Figure 5C (bottom), by reporting data derived from 2.5um channels as originating from 3.5um channels - Figure 6B (top) , by reporting results for the ''Glass'' condition (all treatments) and rescue treatment (both conditions) that did not originate from experimental observations - Figure 6B (bottom), by reporting results for the 8um pore condition that did not originate from experimental observations - Figure 6E , by reporting results for the ATRi and ATMi treatments (Control and KD conditions) and DMSO control (Rescue condition) that did not originate from experimental observations and reporting results as originating from DMSO (Control and KD conditions) controls that had originated from a different treatment - Figure 6G , by reporting results for the ''No Drug'' conditions that did not originate from experimental observations - Figure 6I , by reporting results in all conditions that originated in part from the same experimental dataset reported in Figure 6B (top) - Figure S4D , by reporting results that did not originate from experimental observations for the KD condition - Figure S6C (1) To have her research supervised for a period of three (3) years; Respondent agreed to ensure that prior to the submission of an application for PHS support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHSsupported research, the institution employing her must submit a plan for supervision of Respondent's duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that she will not participate in any PHS-supported research until a plan for supervision is submitted and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon plan for supervision.
(2) that for a period of three (3) years, any institution employing her must submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) if no supervisory plan is provided to ORI, to provide certification to ORI on annual basis that she has not engaged in, applied for, or had her name included on any application, proposal, or other request for PHS funds without prior notification to ORI; (4) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
